^
    13h
    GDFATHER-NSCLC-01: Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC (clinicaltrials.gov)
    P2, N=107, Recruiting, CatalYm GmbH
    Trial initiation date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • visugromab (CTL-002)
    18h
    APHP241011: Impact of the timing of immunotherapy administration in metastatic lung cancers (2025-521891-78-00)
    P2/3, N=254, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • RAS mutation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed
    21h
    SYNSTAR-02: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=680, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | N=450 --> 680 | Initiation date: Mar 2026 --> Jun 2026
    Enrollment change • Trial initiation date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • SYS6010
    1d
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    2d
    Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC (clinicaltrials.gov)
    P2, N=17, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2024 --> May 2026
    Enrollment open • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • pemetrexed
    2d
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    2d
    TroFuse-004: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (clinicaltrials.gov)
    P3, N=556, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR T790M
    |
    docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)
    3d
    A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=156, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Trial completion date: Jun 2027 --> Dec 2029 | Trial primary completion date: Jun 2026 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • pemetrexed • Ameile (aumolertinib) • AiRuiLi (adebrelimab) • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)
    3d
    Leukemia Cutis at Initial Diagnosis of Acute Myeloid Leukemia Consistent With Therapy-Related Disease After Lung Cancer Chemotherapy: A Case Report. (PubMed, Case Rep Hematol)
    A 78-year-old woman with Stage IV NSCLC (adenocarcinoma, no actionable mutations, PD-L1 negative) initially received carboplatin, pemetrexed, and pembrolizumab, complicated by neutropenic fever. She later enrolled in the SHERLOC trial (MM-121 + docetaxel), discontinued due to colitis and neutropenia...The patient received hydroxyurea, transfusion support, and tumor lysis prophylaxis...LC at the time of initial AML diagnosis is uncommon and portends poor prognosis. Clinicians should remain vigilant for new skin lesions and cytopenias in cancer survivors previously exposed to chemotherapy, as early recognition of extramedullary AML may expedite timely diagnosis and care planning.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • DNMT3A (DNA methyltransferase 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • SPN (Sialophorin)
    |
    PD-L1 negative
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • pemetrexed • seribantumab (MM-121) • hydroxyurea
    3d
    Herpes Zoster Following Chemo-Immunotherapy With Pembrolizumab in Metastatic Non-small Cell Lung Cancer: A Case Report. (PubMed, Cureus)
    This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Prolia (denosumab)
    3d
    TPLM: Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Guangzhou Medical University | Trial primary completion date: Jan 2026 --> Jul 2026
    Trial primary completion date • Checkpoint inhibition
    |
    Loqtorzi (toripalimab-tpzi) • pemetrexed
    8d
    Leptomeningeal metastatic disease responding to carboplatin, pemetrexed, and amivantamab after progression to osimertinib in EGFR exon 21 L858R-Mutated non-small cell lung cancer: Two case reports. (PubMed, Respir Med Case Rep)
    To our knowledge, this is the first report to demonstrate the efficacy of carboplatin, pemetrexed, and amivantamab against LMD progression after osimertinib therapy, suggesting that this regimen may be a therapeutic option for patients with LMD, including those with symptomatic disease. Nevertheless, further studies are warranted to confirm efficacy in this population.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed